potassium canrenoate

Potassium canrenoate is a water-soluble, small molecule mineralocorticoid receptor antagonist (MRA) and the primary active metabolite of spironolactone. It functions by competitively inhibiting the mineralocorticoid receptor, thereby blocking the effects of aldosterone and preventing sodium and water retention. In the context of the MINIMISE-STEMI Phase 3 trial led by University College, London, it was investigated as an intravenous pretreatment administered prior to primary percutaneous coronary intervention (PPCI) in patients with ST-elevation myocardial infarction (STEMI). The goal was to reduce myocardial infarct size and prevent adverse left ventricular remodeling. While the trial did not meet its primary endpoint of reducing infarct size, it suggested benefits in preserving cardiac structure. It is clinically available in several European countries but is not FDA-approved.

Brand names

SoldactoneVenactone

Other names

canrenoate potassiumpotassium canrenoic acid